Maarten van der Doelen

Chapter 4

Table 1. Baseline patient demographics and clinical characteristics.

All patients (N=122)

Age, years, median (IQR)

73 (65-78)

Gleason score ≥8, n (%)

80 (65.6)

Time from mCRPC to radium-223, months, median (IQR)

21.4 (10.4-41.6)

Extent of disease, n (%) Low volume (<6 bone metastases)

15 (12.3)

Intermediate volume (6-20 bone metastases)

33 (27.0)

High volume (>20 bone metastases)

62 (50.8)

Superscan

12 (9.8)

Lymph node metastases ≥ 15 mm, n (%)

17 (13.9)

Visceral metastases, n (%)

3 (2.5)

Prior systemic therapies Number of prior registered therapies, median (range)

2 (0-5)

None, n (%)

12 (9.8)

Docetaxel, n (%) †

74 (60.7)

Cabazitaxel, n (%)

18 (14.8)

53 (43.4)

Abiraterone, n (%) ‡

Enzalutamide, n (%)

58 (47.5)

Both Abiraterone and Enzalutamide, n (%)

14 (11.5)

Prior skeletal-related event, n (%)

55 (45.1)

Opioid use, n (%)

40 (32.8)

ECOG performance status, n (%) ECOG 0

51 (41.8)

ECOG 1

53 (43.4)

ECOG 2-3

18 (14.8)

Hemoglobin, mmol/L, median (IQR)

7.8 (7.3-8.3)

Platelet count, x 10 9 /L, median (IQR)

240 (198-286)

PSA, ng/ml, median (IQR)

88 (29-256)

ALP, U/L, median (IQR)

142 (102-234)

LDH, U/L, median (IQR)

234 (204-280)

Concomitant bone protective agent use, n (%)

82 (67.2)

Bisphosphonates

25 (20.5)

Denosumab

57 (46.7)

Charlson comorbidity index, % 6-7

105 (86.1)

96